Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9467310.26442/2075-1753_19.8.2.77-82ArticlesСтатьиResearch ArticleGallstone disease: correct tactic is the key to successful litholysisЖелчнокаменная болезнь: правильная тактика - залог успешного литолизаVyalovS. SВяловСергей Сергеевич

канд. мед. наук, доц. каф. общей практики, врач-гастроэнтеролог, гепатолог GMS clinic & hospitals.

svialov@mail.ruPeople’s Friendship University of RussiaФГАОУ ВО РУДН, ФГБОУ ВО «МГТУ им. Н.Э.Баумана»N.E.Bauman Moscow State Technical UniversityGlobal Medical System clinic & hospitals19082017198-2NO8-2 (2017)Том 19, №8-2 (2017)778228122021Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94673

The article deals with data analysis on the tactic of uncomplicated cholelithiasis treatment, taking into account the features of the diagnostic search. Actual studies of methods of cholelithiasis treatment are discussed, including selection of patients - candidates for therapy, using of various drugs of ursodeoxycholic acid, aspects of costs for treatment. It is necessary to fulfill the requirements for diagnosis and selection of patients for oral litholysis, which ensures the success of therapy. Choosing a treatment it is necessary to take into account the characteristics of the drugs, the quality of production and the substance. For illustration, we analyze the clinical case.

В статье приводится анализ данных по тактике лечения неосложненной желчнокаменной болезни с учетом особенностей диагностического поиска. Рассматриваются актуальные исследования методов медикаментозной терапии желчнокаменной болезни, в том числе отбор пациентов - кандидатов на терапию, использование урсодезоксихолевой кислоты, обсуждаются аспекты затрат на лечение. Необходимым представляется выполнение требований к диагностике и подбору пациентов для перорального литолиза, что обеспечивает успех терапии. Следует учитывать особенности препаратов, качество производства и субстанции при выборе средства терапии. В качестве иллюстрации приводится разбор клинического случая.

cholelithiasisbiliary sludgebiliary dysfunctionursodeoxycholic acidlitholysisжелчнокаменная болезньбилиарный сладжбилиарная дисфункцияурсодезоксихолевая кислоталитолизHeaton K.W, Braddon F.E, Mountford R.A. et al. Symptomatic and silent gall stones in the community. Gut 1991; 32: 316.Everhart J.E, Khare M., Hill M., Maurer K.R. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999; 117: 632.Petroni M.L, Jazrawi R.P, Pazzi P. et al. Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol 2000; 12: 695.Warttig S, Ward S, Rogers G, Guideline Development Group. Diagnosis and management of gallstone disease: summary of NICE guidance. BMJ 2014; 349: g6241.Diehl A.K, Sugarek N.J, Todd K.H. Clinical evaluation for gallstone disease: usefulness of symptoms and signs in diagnosis. Am J Med 1990; 89: 29.Portincasa P, van de Meeberg P., van Erpecum K.J. et al. An update on the pathogenesis and treatment of cholesterol gallstones. Scand J Gastroenterol (Suppl.) 1997; 223: 60.Zakko S.F, Guttermuth M.C, Jamali H. et al. A population study of gallstone composition, symptoms, and outcomes after cholecystectomy (abstract). Gastroenterology 1999; 116: A43.Berger M.Y, van der Velden J.J, Lijmer J.G. et al. Abdominal symptoms: do they predict gallstones? A systematic review. Scand J Gastroenterol 2000; 35: 70.Sherlock S., Dooley J. Diseases of the liver and biliary system, Blackwell Science, Oxford, 2002.Ko C.W, Sekijima J.H, Lee S.P. Biliary sludge. Ann Intern Med 1999; 130: 301.Festi D, Reggiani M.L, Attili A.F. et al. Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol 2010; 25: 719.Caroli A,. Del Favero G, Di Mario F. et al. Computed tomography in predicting gall stone solubility: a prospective trial. Gut 1992; 33: 698.Shea J.A, Berlin J.A, Escarce J.J et al. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med 1994; 154: 2573.Johnson C.D. ABC of the upper gastrointestinal tract. Upper abdominal pain: Gall bladder. BMJ 2001; 323: 1170.Colli A, Conte D, Valle S.D. et al. Meta-analysis: nonsteroidal anti-inflammatory drugs in biliary colic. Aliment Pharmacol Ther 2012; 35: 1370.Berger M.Y, Olde Hartman T.C, Bohnen A.M. Abdominal symptoms: do they disappear after cholecystectomy? Surg Endosc 2003; 17: 1723.Diehl A.K. Gallstone size and the risk of gallbladder cancer. JAMA 1983; 250: 2323.Festi D, Reggiani M.L., Attili A..F et al. Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol 2010; 25: 719.Soper N.J, Stockmann P.T, Dunnegan D.L, Ashley S.W. Laparoscopic cholecystectomy. The new “gold standard”? Arch Surg 1992; 127: 917.Shao T., Yang Y.X. Cholecystectomy and the risk of colorectal cancer. Am J Gastroenterol 2005; 100: 1813.Tomida S., Abei M., Yamaguchi T. et al. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology 1999; 30: 6.Tint G.S, Salen G, Colalillo A. et al. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med 1982; 97: 351.Rubin R.A, Kowalski T.E, Khandelwal M, Malet P.F. Ursodiol for hepatobiliary disorders. Ann Intern Med 1994; 121: 207.Fromm H, Malavolti M. Bile acid dissolution therapy of gallbladder stones. Baillieres Clin Gastroenterol 1992; 6: 689.Trotman B.W, Soloway R.D. Pigment vs cholesterol cholelithiasis: clinical and epidemiological aspects. Am J Dig Dis 1975; 20: 735.Guarino M.P, Cong P, Cicala M. et al. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut 2007; 56: 815.Guarino M.P, Cocca S, Altomare A.et al. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol 2013; 19: 5029.Di Ciaula A, Wang D.Q, Wang H.H et al. Targets for current pharmacologic therapy in cholesterol gallstone disease. Gastroenterol Clin North Am 2010; 39: 245.Сарвилина И.В. Сравнительный клинико-экономический анализ применения препаратов урсодезоксихолевой кислоты у пациентов с желчнокаменной болезнью стадии. Лечащий врач. 2015; 2.Вялов С.С., Степченко А.А., Дронова Т.А., Винницкая Е.В. Выбор препарата для лекарственной терапии с учетом особенностей субстанции. Арх. внутренней медицины. 2012; 4 (6): 34-8.